Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Study identifier:D1060C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers with Lung Metastasis in the Expansion Phase.

Medical condition

solid malignancies

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD1480

Sex

All

Actual Enrollment

38

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 Apr 2010
Primary Completion Date: 01 Sept 2012
Study Completion Date: 01 Sept 2012

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria